News

The DDI Marker Studies Knowledgebase has been updated in January 2025 and is available in the DIDB Resource Center.

In this update, we have continued identifying substrates, inhibitors, and inducers for CYP enzymes and various transporters. A total of 20 compounds were characterized, including substates of CYP2C9, CYP3A, BCRP, OAT1, and OAT3, inhibitors of CYP2C19, CYP2D6, P-gp, BCRP, and OCT2, and inducers of CYP2C19 and P-gp. No strong perpetrators or sensitive substrates were identified.

To view a comprehensive list of additions and modifications, including new compounds and updates to existing entries, you may use the “Recent Update” column (Column AE) on the spreadsheet and select “yes.”

In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g., dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.

As always, feel free to contact us if you have any questions or comments.

In December, we added 106 citations in DIDB, including 56 in vitro (with 22 articles published in December 2024) and 50 in vivo articles (with 41 articles published in December 2024).

3 NDA/BLAs approved in 2024, including revumenib (REVUFORJ), sulopenem and probenecid (ORLYNVAH), and zanidatama (ZIIHERA) were also curated in DIDB.

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

In November, we added 93 citations in DIDB, including 45 in vitro (with 26 articles published in November 2024) and 48 in vivo articles (with 34 articles published in November 2024).

5 NDA/BLAs approved in 2024, including arimoclomol (MIPLYFFA), inavolisib (ITOVEBI), seladelpar (LIVDELZI), zolbetuixmab(VYLOY), and xanomeline and trospium (COBENFY) were also curated in DIDB.

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

In October, we added 115 citations in DIDB, including 55 in vitro (with 23 articles published in October 2024) and 60 in vivo articles (with 35 articles published in October 2024).

3 NDA/BLAs approved in 2024, including lebrikizumab (EBGLYSS), levacetylleucine (AQNEURSA), and flurpiridaz F18 (FLYRCADO) were also curated in DIDB.

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

The DDI Marker Studies Knowledgebase has been updated in October 2024 and is available in the DIDB Resource Center.

Our Editorial Team has dedicated effort on identifying substrates and perpetrators of UGT enzymes. More than 30 UGT substrates, inhibitors, and inducers recommended by the ICH M12 DDI guideline have been added to the knowledgebase with supporting DDI and/or PGx evidence. In addition, we have continued to identify substrates and inhibitors for renal transporters by reviewing all the existing data. Overall, 65 compounds have been identified as substates, inhibitors, and inducers of CYPs, UGTs, and various transporters, including P-gp, BCRP, OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, and MATE2-K. Notably, one compound was classified as a sensitive substrate of CYP1A2 and one as a strong inhibitor of CYP3A based on PBPK data (AUCR > 10), which could potentially lead to significant drug interactions mediated by these CYPs.

To view a comprehensive list of additions and modifications, including new compounds and updates to existing entries, you may use the “Recent Update” column (Column AE) on the spreadsheet and select “yes.”

In addition to substrates, inhibitors and inducers of CYPs and transporters, the Knowledgebase provides useful information on the compounds therapeutic class, clinical recommended dosage, pharmacokinetics (e.g., dose proportionality accumulation ratio, time to steady-state), QT prolongation, and NTI characteristics.

As always, feel free to contact us if you have any questions or comments.

In September, we added 83 citations in DIDB, including 44 in vitro (with 24 articles published in September 2024) and 39 in vivo articles (with 27 articles published in September 2024).

6 NDA/BLAs approved in 2024, including axatilimab (NIKTIMVO), deuroxolitinib (LEQSELVI), lazertinib (LAZCLUZE), nemolizumab (NEMLUVIO), palopegteriparatide (YORVIPATH), and vorasidenib (VORANIGO), were also curated in DIDB.

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.

In August, we added 115 citations in DIDB, including 47 in vitro (with 28 articles published in August 2024) and 68 in vivo articles (with 38 articles published in August 2024).

2 NDA/BLAs approved in 2024, including elafibranor (IQIRVO) and donanemab (KISUNLA), were also curated in DIDB.

You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.

As always, feel free to contact us if you have any questions or comments.